中国药房2024，Vol.35Issue(14)：1770-1775,6.DOI:10.6039/j.issn.1001-0408.2024.14.17
沙库巴曲缬沙坦对原发性高血压患者肾功能的影响
Effects of sacubitril/valsartan on renal function in patients with primary hypertension
谢雅君 1赵蓓 2冯雪瑶 2李世兴 3李晓晔 1史宁1
作者信息
- 1. 战略支援部队特色医学中心药剂科,北京 100101
- 2. 战略支援部队特色医学中心心内科,北京 100101
- 3. 解放军总医院心血管病医学部派驻第一医学中心心内科,北京 100853
- 折叠
摘要
Abstract
OBJECTIVE To investigate the effects of sacubitril/valsartan on renal function in patients with primary hypertension.METHODS A retrospective study was conducted among patients with primary hypertension who were admitted to PLA Strategic Support Force Characteristic Medical Center from January 2018 to June 2023.Based on their medication,they were divided into two groups:sacubitril/valsartan group and valsartan group.Propensity score matching was used to match baseline data between the two groups.Patients were treated with antihypertensive drugs based on improving their lifestyle.Sacubitril/valsartan group additionally received oral administration of 200 mg Sacubitril/valsartan tablets once daily,while valsartan group additionally received oral administration of 80 mg Valsartan capsules once daily.The increase amplitude of serum creatinine from baseline,the proportion of patients with elevated serum creatinine＞30%-50%or＞50%,and the proportion of patients with hyperkalemia(serum potassium≥5.5 mmol/L)were compared between two groups at 2 months and 6 months after treatment.The trends of changes in serum creatinine,serum potassium and estimated glomerular filtration rate(eGFR)were compared between the two groups before treatment(at baseline),2 months and 6 months after treatment.RESULTS After propensity score matching,there were 62 patients in sacubitril/valsartan group and 61 patients in valsartan group;there were no significant differences in baseline characteristics between the two groups before treatment(P＞0.05),indicating comparability.After 6 months of treatment,the increase of serum creatinine in the sacubitril/valsartan group was significantly lower than that in the valsartan group(P=0.003);the proportion of patients with elevated serum creatinine＞30%-50%in the sacubitril/valsartan group was significantly lower than that in the valsartan group(P=0.045).None of the patients experienced hyperkalemia events after 2 months and 6 months of treatment.Repeated measures analysis of variance showed significantly statistical differences in serum creatinine and eGFR between the two groups within 6 months of treatment(P＜0.001).Patients taking valsartan experienced a continuous increase in serum creatinine levels and a decrease in eGFR,while patients taking sacubitril/valsartan showed a first increase and then a decrease in serum creatinine levels,and a first decrease and then an increase in eGFR with a prolonged duration of medication.CONCLUSIONS Sacubitril/valsartan can delay or even reverse the decline in renal function levels,and limit the deterioration of renal function in patients with primary hypertension,without increasing the risk of hyperkalemia.关键词
沙库巴曲缬沙坦/原发性高血压/肾功能/血肌酐/血钾/估算肾小球滤过率Key words
sacubitril/valsartan/primary hypertension/renal function/serum creatinine/serum potassium/eGFR分类
医药卫生引用本文复制引用
谢雅君,赵蓓,冯雪瑶,李世兴,李晓晔,史宁..沙库巴曲缬沙坦对原发性高血压患者肾功能的影响[J].中国药房,2024,35(14):1770-1775,6.
